XORTX Therapeutics Inc. ("
XORTX" or the
“
Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt:
ANU), a late-stage clinical pharmaceutical company focused on
developing innovative therapies to treat progressive kidney
disease, is pleased to announce presentation of scientific data
underpinning the recent Orphan Drug Designation
(“
ODD”) at the PKD Foundation – “PKD Connect”
meeting being held June 22-24, 2023 in Denver, Colorado. The
studies to be presented were conducted by Dr. Charles Edelstein of
the University of Colorado and represent the seminal research
leading to the US Food and Drug Administration ODD grant that was
announced by the Company on April 21, 2023. This annual meeting of
the US PKD Foundation (https://pkdcure.org/conference/) is attended
by leading thought leaders, PKD foundation members, patient
advocacy groups and medical researchers interested in autosomal
dominant polycystic kidney disease (“
ADPKD”).
Dr. Allen Davidoff stated: “This presentation
will review the discoveries made by Dr. Charles Edelstein, with
XORTX sponsorship. The discoveries show that aberrant purine
metabolism in polycystic kidneys tissue may play a role in disease
progression, that chronic high uric acid can promote kidney
expansion and declining filtering capacity, most importantly that
XORLOTM can attenuate polycystic kidney disease progression. The
PKD annual meeting provides an opportunity to interact with patient
groups, knowledge leaders in ADPKD research in the US and is an
important step towards advancing the XRx-008 program. We believe
xanthine oxidase inhibition represents an important approach to
slowing the progression of kidney disease and improved quality of
life for those individuals ADPKD and few therapeutic options.”
XORTX Annual and Special Meeting of
Shareholders
In connection with the Company’s annual and
special meeting of shareholders (the “Meeting”)
that has been scheduled for Wednesday, June 28, 2023 at 10:00 am
(Calgary time), the Company has retained Laurel Hill Advisory Group
(“Laurel Hill”) as proxy solicitation agent and
shareholder communications advisor to, among other things, assist
in the solicitation of proxies. The Company may use Broadridge
Financial Solutions Inc.’s QuickVote™ service to assist beneficial
shareholders with voting. Laurel Hill may contact certain
beneficial shareholders who have not objected to the Company
knowing who they are (non-objecting beneficial owners, or NOBOs) to
conveniently obtain a vote directly over the telephone.
At the Meeting, XORTX shareholders will vote on
the following resolutions:
- To elect directors of the Company;
- To appoint the auditor of the Company for the ensuing year and
to authorize the directors of the Company to fix the remuneration
of the auditor; and
- To confirm and approve the Company’s stock option plan.
The notice and management information circular
are available on XORTX’s profile on SEDAR (www.sedar.com).
Shareholders are encouraged to read the Circular
and vote your shares as soon as possible. The deadline for voting
your shares is at 10:00 a.m. (Calgary time) on Monday, June 26,
2023.
Shareholders who have any questions or require
assistance with voting may contact the Company’s proxy solicitation
agent and shareholder communications advisor:
Laurel Hill Advisory Group
Toll Free: 1-877-452-7184 (for shareholders in
North America)International: +1 416-304-0211 (for shareholders
outside Canada and the US)By Email: assistance@laurelhill.com
About Orphan Drug Designation
Drugs intended to
treat orphan diseases (rare diseases that affect less than 200,000
people in the US) are eligible to apply for ODD, which
provides multiple benefits to the sponsor during development and
after approval. XORTX intends to pursue these benefits as part of
the drug development for XRx-008 for treatment of ADPKD.
About ADPKD
ADPKD is a rare disease that affects more that
10 million individuals worldwide.1,2 ADPKD is typically diagnosed
based upon expansion of fluid-filled cysts in the kidneys. Over
time, the increasing number and size of cysts can contribute to
structural and functional changes to kidneys and is frequently
accompanied by chronic pain which is a common problem for patients
with ADPKD.3 Expansion of cysts is thought to compress healthy
functioning tissue surrounding the cysts and contribute to further
loss of kidney function, fibrosis, impaired nutrient exchange and
impaired kidney function, accompanied later by end-stage renal
disease.1 For individuals with progressing ADPKD, treatment
recommendations include anti-hypertensive treatment, dietary
restrictions, and, for a limited percentage of suitable patients,
pharmacotherapy.4 New, more broadly applicable therapies to
effectively slow decline of kidney function in ADPKD are
needed.
About the XRx-008 Program
Oxypurinol is a xanthine oxidase inhibitor
(“XOI”) with important pharmacologic
characteristics ideal for administration to individuals with ADPKD.
Key pharmacologic attributes include:
1/ The ability to act in the circulation, kidney
and cardiovascular tissue and inhibit the production of uric acid
and so attenuate the mechanism of injury and accelerating effect of
xanthine oxidase on progressing diseases.
2/ XORLOTM provides substantially increased
absorption of oxypurinol. This approach provides an effective, well
tolerated drug with an extensive clinical safety experience
suggesting the Company’s XRx-008 program has the capacity to
provide superior XOI to slow the accelerating decline in kidney
function during ADPKD progression.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two
clinically advanced products in development: 1) our lead, XRx-008
program for ADPKD; and 2) our secondary program in XRx-101 for
acute kidney and other acute organ injury associated with
Coronavirus / COVID-19 infection. In addition, XRx-225 is a
pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX
is working to advance its clinical development stage products that
target aberrant purine metabolism and xanthine oxidase to decrease
or inhibit production of uric acid. At XORTX, we are dedicated to
developing medications to improve the quality of life and future
health of patients. Additional information on XORTX is available at
www.xortx.com.
For more information, please contact:
Allen
Davidoff, CEO |
Nick
Rigopulos, Director of Communications |
adavidoff@xortx.com or +1 403 455 7727 |
nick@alpineequityadv.com or +1 617 901 0785 |
Media Inquiries, David Melamed,
Ph.D.david.melamed@russopartnersllc.com or +1 212 845 4225
References:
- Wiley C., Kamat S., Stelhorn R.,
Blais J., Analysis of nationwide date to determine the incidence
and diagnosis of autosomal dominant polycystic kidney disease in
the USA, Kidney Disease, 5(2): 107-117, 2019
- Bergmann C., Guay-Woodford L.M.,
Harris P.C., Horie S., Peters D.J., Torres V.E., Polycystic Kidney
Disease, Nat Rev Dis Primers. 4(1): 50, 2018
-
https://pkdcure.org/living-with-pkd/chronic-pain-management/
- Gimpel C., Bermann C., Bockenhauer
D., et al., International consensus statement of the diagnosis and
management of autosomal dominant polycystic kidney disease in
children and young people, Nat Rev Nephrol 15(11):713-726,
2019
Neither the TSX Venture Exchange nor Nasdaq has
approved or disapproved the contents of this news release. No stock
exchange, securities commission or other regulatory authority has
approved or disapproved the information contained herein.
Forward Looking Statements
This press release contains express or implied
forward-looking statements pursuant to U.S. Federal securities
laws. These forward-looking statements and their implications are
based on the current expectations of the management of XORTX only,
and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements. Except as otherwise required by
law, XORTX undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting XORTX is contained under the heading “Risk
Factors” in XORTX’s Registration Statement on Form F-1 filed with
the SEC, which is available on the SEC's website, www.sec.gov
(including any documents forming a part thereof or incorporated by
reference therein), as well as in our reports, public disclosure
documents and other filings with the securities commissions and
other regulatory bodies in Canada, which are available on
www.sedar.com.
Xortx Therapeutics (TSXV:XRTX)
過去 株価チャート
から 5 2024 まで 6 2024
Xortx Therapeutics (TSXV:XRTX)
過去 株価チャート
から 6 2023 まで 6 2024